Today's Rundown Featured Story | | | Monday, March 2, 2020 The takeover will give Gilead control of midphase anti-CD47 antibody magrolimab that delivered data that impressed investors late last year. |
|
|---|
|
Top Stories Sunday, March 1, 2020 The chief executive of infectious disease biotech Vir, George Scangos, has been handed the reins to lead the biotech industry’s battle against the novel coronavirus COVID-19. Monday, March 2, 2020 Sam Waksal’s attempt to buy Redx Pharma has fallen apart. The failure of a company set up by the once-jailed biotech executive to close a deal led Redx to turn to Redmile for the cash to keep going until next month. Monday, March 2, 2020 Immunocore has raised a $130 million (€117 million) series B round, ending its long wait for fresh funding. The British biotech made waves in 2015 with a $320 million series A but reportedly had to slash the near-unicorn valuation it achieved back then to get the latest round off the ground. Monday, March 2, 2020 As it gears up to move its immuno-oncology programs into the clinic, Akrevia Therapeutics has reeled in a $100.5 million series B and changed its name to Xilio Therapeutics to mark its transition from a research-focused company to an R&D-stage one. Sunday, March 1, 2020 To broaden capacity and access to coronavirus diagnostics in the U.S., the FDA issued a new policy over the weekend allowing “high-complexity” laboratories—such as certain academic medical centers and other institutions—to develop and operate their own tests. Wednesday, February 12, 2020 As the global outbreak rolls on, U.S. case confirmations grew over the weekend and into Monday. Now, former FDA commissioner Scott Gottlieb says to expect "mitigation steps" such as school closings and transportation restrictions in certain areas. Enrollment Showcase | | | Presented by: Global EMBA for Healthcare & the Life Sciences, University of Toronto Prepare to step up in your career, build the expertise you need to reshape your organization, and explore opportunities worldwide. |
|
|---|
|
Resources Sponsored by: Epsilon Download this e-book to learn 9 ways to enhance the customer experience within healthcare marketing. Sponsored by: Reprints Desk/Research Solutions 3 ways you may be overspending on scientific literature access, and how to fix them. Sponsored by: Baxter When different drug products are produced in shared facilities, potential for cross-contamination needs to be addressed. Outsourcing to a CMO with experience in multiproduct facilities can be an option. Sponsored by: WCG Metrics Champion Consortium Ineffective measurement could mean wasting both time and money. This whitepaper showcases a custom-built Metric Maturity Model that helps illustrate and define the process for measuring the right things the right way. Sponsored by: Eagle Productivity Solutions Mediocre adoption rates aren’t due to poorly designed software or lazy users. They’re the result of how skills are trained. Achieve high adoption rates by implementing the right methodology with a focus on behavior change. Sponsored by: The Kinetix Group Read about the innovative ways payers are making smart moves in the healthcare game. Sponsored by: H1 Biopharma companies don't want to go to market with a product no one knows about. H1 has homed in on the often time-consuming research and engagement phases that companies must ace for a successful launch, said Ariel Katz, co-founder of H1. Sponsored by: Clinical Ink Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Accenture Kevin Julian, senior managing director of Accenture’s life sciences practice, recently sat down with FierceBiotech to discuss market trends and Accenture’s new technology platform, INTIENT. Sponsored by: Blue Matter Consulting White paper describing how a biopharma company can successfully differentiate an oncology product when the clinical profile alone is not enough to get the job done. Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. | 
